Group 1 - Xi'an Deyi Group Co., Ltd. (referred to as Deyi Group) submitted its Hong Kong IPO prospectus on April 28, which became invalid after six months on October 28 [1] - The joint sponsors for the IPO are CITIC Securities International, Pudong Development Bank International, and Minyin Capital [1] Group 2 - Deyi Group is a global leader in innovative radiosurgery solutions, aiming to build a next-generation intelligent radiosurgery ecosystem [3] - Since its establishment in 2011, the company has developed a comprehensive treatment matrix, including multiple solutions that are either approved or in development [3] - The core product, CybeRay, is the world's first real-time image-guided gamma radiosurgery system, which received FDA approval in March 2021 and National Medical Products Administration approval in July 2022, and is currently in the research phase for expanding indications [3] - Another flagship product, TaiChiRT Pro, is the world's first integrated radiation therapy system with both X-ray and gamma-ray capabilities, recognized as a breakthrough medical device by the FDA [3]
大医集团港股IPO招股书失效
Zhi Tong Cai Jing·2025-10-27 23:08